Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MICA protein as a plasma biomarker for dermatomyositis with malignancy: a proteome-wide Mendelian randomization and ELISA study.

Clinical rheumatology - 1 Jan 2026

He Kaile, Ye Jiaqi, Shao Xinlin, Teng Jiaming, Ye Mingyu, Zheng Jie, Cao Hua

Abstract excerpt

INTRODUCTION: Dermatomyositis (DM) is an autoimmune disease marked by distinctive cutaneous manifestations and systemic involvement, including an increased risk of malignancy. Proteome-wide Mendelian randomization (MR) revealed plasma major histocompatibility complex class I-related chain A (MICA) as a potential malignancy biomarker in DM, followed by validation with the enzyme-linked immunosorbent assay (ELISA)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dermatomyositis

Share to Enzyme-Linked Immunosorbent Assay

Share to Finland

Share to Histocompatibility Antigens Class I

Share to Mendelian Randomization Analysis

Share to Neoplasms

Source

Identifiers

PMID: 41239078
DOI: 10.1007/s10067-025-07751-y

Genes

MICA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MICA protein as a plasma biomarker for dermatomyositis with malignancy: a proteome-wide Mendelian randomization and ELISA study.PMID 41239078Read ↗

Identifying novel risk targets in inflammatory skin diseases by comprehensive proteome-wide Mendelian randomization studySemantic proximity Read ↗

Analysis of the Potential Link Between Dermatomyositis and CancerSemantic proximity Read ↗

Plasma proteins and inflammatory dermatoses: proteome-wide Mendelian randomization and colocalization analyses.Semantic proximity Read ↗

Mendelian randomization for autoimmune diseases: exploring causal links and drug targets in plasma proteomeSemantic proximity Read ↗

Integrated multi-dimensional analyses reveal a BTN3A2-centered diagnostic risk score and a monocyte-T cell axis as central drivers of dermatomyositis.Semantic proximity Read ↗

Systematic proteome-wide Mendelian randomization to prioritize causal plasma proteins for skin cancers.Semantic proximity Read ↗

Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis.Semantic proximity Read ↗

Proteome-wide Mendelian randomization and colocalization analysis identify therapeutic targets for cutaneous melanomaSemantic proximity Read ↗

A new proposal for phenotypic classification and outcome assessment of dermatomyositis based on clinical manifestations and serological testing.Semantic proximity Read ↗

Exploring novel drug targets for atopic dermatitis through plasma proteome with genome.Semantic proximity Read ↗

Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization studySemantic proximity Read ↗

Identification of Biomarkers Associated With CD4+ T-Cell Infiltration With Gene Coexpression Network in DermatomyositisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.